CRISPR/CAS-related methods and compositions for treating cystic fibrosis
Disclosed herein are genome editing systems and compositions that target a cystic fibrosis transmembrane conductance regulator (CFTR) gene and a sodium channel epithelial 1 alpha (SCNN1A) gene, comprising a Cas9 molecule, and a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a CFTR gene or a SCNN1A gene, and cells comprising such genome editing systems and compositions. Also provided are methods for using the genome editing systems, compositions, and cells for genome engineering (e.g., altering a CFTR gene and/or a SCNN1A gene), and for preventing or treating Cystic Fibrosis (CF) and CF-like disease.
1. A CRISPR/Cas system, comprising:
a) a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a cystic fibrosis transmembrane conductance regulator (CFTR) gene or a sodium channel epithelial 1 alpha (SCNN1A) gene, wherein said target sequence of said CFTR gene is within intron 2 or intron 10 of said CFTR gene; and
b) a Cas9 molecule,
wherein said targeting domain that is complementary to said CFTR gene comprises or consists of a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 15101-27265 and wherein said targeting domain that is complementary to said SCNN1A gene comprises or consists of a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 497-654, 803-916, and 4176-15100.
2. The system of claim 1 , wherein said targeting domain that is complementary to said CFTR gene comprises or consists of a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 15101-27265.
3. The system of claim 1 , wherein said targeting domain that is complementary to said SCNN1A gene comprises or consists of a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 497-654, 803-916, and 4176-15100.
4. A gRNA molecule comprising a targeting domain that is complementary with a target sequence of a CFTR gene or a SCNN1A gene, wherein the target sequence of the CFTR gene is within intron 2 or intron 10 of the CFTR gene, wherein said targeting domain that is complementary to said CFTR gene comprises or consists of a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 15101-27265 and wherein said targeting domain that is complementary to said SCNN1A gene comprises or consists of a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 497-654, 803-916, and 4176-15100.
5. The gRNA molecule of claim 4 , wherein said targeting domain that is complementary to said CFTR gene comprises or consists of a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence set forth in SEQ ID NOs: 15101-27265.
6. The gRNA molecule of claim 4 , wherein said targeting domain that is complementary to said SCNN1A gene comprises or consists of a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence set forth in SEQ ID NOs: 497-654, 803-916, and 4176-15100.
7. A CRISPR/Cas system, comprising:
a) a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a cystic fibrosis transmembrane conductance regulator (CFTR) gene or a sodium channel epithelial 1 alpha (SCNN1A) gene, wherein said target sequence of said CFTR gene is within intron 2 or intron 10 of said CFTR gene, wherein said targeting domain that is complementary to said SCNN1A gene comprises a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 497-654, 803-916, and 4176-15100 and wherein said targeting domain that is complementary to said CFTR gene comprises a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 15101-27265;
b) a Cas9 molecule; and
c) a cDNA donor template that alters said CFTR gene or SCNN1A gene, wherein said cDNA donor template that alters said CFTR gene comprises (a) contiguous coding sequence of exon 3 through exon 27 of said CFTR gene; or (b) contiguous coding sequence of exon 11 through exon 27 of said CFTR gene.
8. A composition comprising:
a) a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a CFTR gene or a SCNN1A gene, wherein the target sequence of the CFTR gene is within intron 2 or intron 10 of the CFTR gene, wherein said targeting domain that is complementary to said SCNN1A gene comprises a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 497-654, 803-916, and 4176-15100 and wherein said targeting domain that is complementary to said CFTR gene comprises a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 15101-27265; and
b) a cDNA donor template that alters said CFTR gene or SCNN1A gene, wherein said cDNA donor template that alters said CFTR gene comprises (a) contiguous coding sequence of exon 3 through exon 27 of said CFTR gene; or (b) contiguous coding sequence of exon 11 through exon 27 of said CFTR gene.
9. A nucleic acid composition that comprises:
a) a first nucleotide sequence that encodes a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a CFTR gene or a SCNN1A gene, wherein the target sequence of the CFTR gene is within intron 2 or intron 10 of the CFTR gene, wherein said targeting domain that is complementary to said SCNN1A gene comprises a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 497-654, 803-916, and 4176-15100 and wherein said targeting domain that is complementary to said CFTR gene comprises a nucleotide sequence that is the same as, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from the targeting domain sequences set forth in SEQ ID NOs: 15101-27265; and
b) a template nucleic acid comprising a cDNA donor template that alters said CFTR gene or SCNN1A gene, wherein said cDNA donor template that alters said CFTR gene comprises (a) contiguous coding sequence of exon 3 through exon 27 of said CFTR gene; or (b) contiguous coding sequence of exon 11 through exon 27 of said CFTR gene.